Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab and EDP1503 in Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Status
- COMPLETED
- Phase
- PHASE1
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- Status
- RECRUITING
- Phase
- PHASE2
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1